Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.>
You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.
Brand Name(s) include: Malarone
Disease: Malaria
Drug Class: Antimalarials
Date Updated: March 2021
Absorption Model |
|
Volume of Distribution |
Note: A Kp scalar (0.04) was used in the model |
Route of Elimination |
|
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
Disease: Malaria
Drug Class: Antimalarials
Date Updated: March 2022
Related Files: Primaquine (parent)
Absorption Model |
N/A |
Volume of Distribution |
Full PBPK (Method 2) |
Route of Elimination |
|
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
Brand Name(s) include: Coartem
Disease: Malaria
Drug Class: Antimalarials
Date Updated: June 2021
Absorption Model |
First-Order |
Volume of Distribution |
Note: A Kp scalar (0.5) was used in the model along with optimized partitioning into adipose tissue (Kp,adipose = 0.5) to recover the clinical observed data. |
Route of Elimination |
|
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
Brand Name: Edurant, Rekambys
Disease: HIV
Drug Class: non-nucleoside reverse transcriptase inhibitor
Version: 21
Date Updated: March 2024
Absorption Model |
First order |
Volume of Distribution Details |
Full PBPK (Method 3) |
Route of Elimination |
|
Perpetrator DDI |
|
Validation |
The refined model was able to recover clinically observed concentration-time profiles of rilpivirine following single and multiple dosing. Seven clinical DDI studies where rilpivirine was administered with either efavirenz, ketoconazole, rifampin, or rifabutin were used to verify the PBPK model of rilpivirine as a victim. In comparison of predicted vs. observed AUC, 85.7% of the studies were within 1.5-fold. Three clinical DDI studies where rilpivirine was administered with either sildenafil, ethinylestradiol, or midazolam were used to verify the PBPK model of rilpivirine as a perpetrator. In comparison of predicted vs. observed AUC, 100% of the studies were within 1.25-fold. |
Limitations |
The net in vivo effect of rilpivirine as either an inhibitor or an inducer of CYP3A appears to be negligible based on the available DDI studies |
4 |